ORKA Oruka Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—
Leverage & solvency
Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | $0 |
| R&D expense | $100.64M | $1.01M | $4.75M | $13.83M | $4.99M |
| SG&A expense | $21.41M | $6.28M | $5.85M | $5.50M | $4.77M |
| Operating income | -$122.05M | -$7.30M | -$10.60M | -$19.34M | -$9.77M |
| Interest expense | — | — | — | — | $9,000 |
| Pretax income | -$105.43M | — | — | -$19.32M | -$9.75M |
| Income tax | — | $0 | $0 | $0 | -$9,000 |
| Net income | -$105.43M | -$5.34M | -$9.93M | -$19.32M | -$9.74M |
| EBITDA | -$121.97M | -$7.28M | -$10.58M | -$19.32M | -$9.76M |
| EPS (basic) | — | -0.37 | -0.69 | -1.39 | -2.07 |
| EPS (diluted) | — | -0.37 | -0.69 | -1.39 | -2.07 |
| Weighted avg. shares (diluted) | — | 14.42M | 14.41M | 13.90M | 4.71M |
| Balance sheet | |||||
| Cash & equivalents | $46.94M | $37.43M | $42.45M | $53.36M | $49.07M |
| Short-term investments | $290.11M | — | — | — | — |
| Current assets | $343.86M | $37.59M | $42.70M | $54.42M | $49.97M |
| PP&E, net | $288,000 | $10,000 | $25,000 | $48,000 | $21,000 |
| Total assets | $488.62M | $37.86M | $43.09M | $54.92M | $50.43M |
| Current liabilities | $15.37M | $637,000 | $1.13M | $3.50M | $3.50M |
| Total liabilities | $16.69M | $841,000 | $1.41M | $3.88M | $3.91M |
| Shareholders' equity | $471.93M | $37.02M | $41.67M | $51.04M | $46.52M |
| Shares outstanding | 48.72M | 14.50M | 14.41M | 14.41M | 9.55M |
| Cash flow statement | |||||
| Operating cash flow | -$88.21M | -$5.01M | -$10.91M | -$18.76M | -$7.72M |
| Capital expenditure | $209,000 | $0 | $2,000 | $43,000 | $19,000 |
| Free cash flow | -$88.42M | -$5.01M | -$10.91M | -$18.80M | -$7.74M |
| Investing cash flow | -$96.75M | $0 | -$2,000 | -$43,000 | -$19,000 |
| Financing cash flow | $170.31M | $0 | $0 | $23.09M | $48.45M |
| Depreciation & amortization | $83,000 | $15,000 | $20,000 | $16,000 | $8,000 |
| Stock-based compensation | $24.24M | $686,000 | $556,000 | $497,000 | $43,000 |
Free plan shows the latest 5 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.